Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
In the LEADER trial, liraglutide demonstrated cardiovascular benefit, and GLP1RAs have similar effects, aligning with liraglutides anti-atherosclerotic effect
Forward-looking statements in this press release include, without limitation, statements regarding: the promise and potential impact of our clinical trial data and product candidates, including Revitas potential for maintaining weight loss after GLP-1 based therapy discontinuation and stabilize cardiometabolic parameters
Over 12 weeks, our group saw a mean IIEF-5 increase from 13.8 to 19.1, with the largest gains in erection rigidity and maintenance
Sources: All data and statements above are based on current industry news, company releases, and expert analyses
